Clinical trial · no report yet · Phase 3
MajesTEC-7
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT05552222 ↗
- Recruiting
- Janssen Research & Development, LLC
- 36 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 19 | |
| X threads | 9 | |
| Podcasts | 8 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab; Daratumumab; Lenalidomide; Dexamethasone; Talquetamab
- Arms
- Teclistamab, Daratumumab SC, and Lenalidomide (Tec-DR) · Experimental
- Talquetamab, Daratumumab SC, and Lenalidomide (Tal-DR) · Experimental
- Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) · Active comparator
- Enrollment
- 1,590 (estimated)
- Primary outcomes
- Progression Free Survival (PFS)
- 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Oct 25, 2022
- Primary completion
- Apr 30, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT05552222 · updated Sep 25, 2026